RU2014114617A - Комбинированные виды лечения, содержащие антагонисты с-мет и антагонисты b-raf - Google Patents
Комбинированные виды лечения, содержащие антагонисты с-мет и антагонисты b-raf Download PDFInfo
- Publication number
- RU2014114617A RU2014114617A RU2014114617/10A RU2014114617A RU2014114617A RU 2014114617 A RU2014114617 A RU 2014114617A RU 2014114617/10 A RU2014114617/10 A RU 2014114617/10A RU 2014114617 A RU2014114617 A RU 2014114617A RU 2014114617 A RU2014114617 A RU 2014114617A
- Authority
- RU
- Russia
- Prior art keywords
- antagonist
- raf
- patient
- met
- biomarker
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims abstract 84
- 238000011282 treatment Methods 0.000 title claims 9
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 title 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 title 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims abstract 68
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims abstract 68
- 238000000034 method Methods 0.000 claims abstract 56
- 201000011510 cancer Diseases 0.000 claims abstract 31
- 239000000090 biomarker Substances 0.000 claims abstract 25
- 230000014509 gene expression Effects 0.000 claims abstract 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract 8
- 230000035945 sensitivity Effects 0.000 claims abstract 7
- 230000001404 mediated effect Effects 0.000 claims abstract 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 8
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 8
- 238000004458 analytical method Methods 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 5
- -1 cabosanthinib Chemical compound 0.000 claims 3
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 3
- 238000003364 immunohistochemistry Methods 0.000 claims 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 2
- 229960003862 vemurafenib Drugs 0.000 claims 2
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims 1
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 claims 1
- JRWCBEOAFGHNNU-UHFFFAOYSA-N 6-[difluoro-[6-(1-methyl-4-pyrazolyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline Chemical compound C1=NN(C)C=C1C1=NN2C(C(F)(F)C=3C=C4C=CC=NC4=CC=3)=NN=C2C=C1 JRWCBEOAFGHNNU-UHFFFAOYSA-N 0.000 claims 1
- HEAIZQNMNCHNFD-UHFFFAOYSA-N AMG-208 Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OCC(N1N=2)=NN=C1C=CC=2C1=CC=CC=C1 HEAIZQNMNCHNFD-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 claims 1
- UFICVEHDQUKCEA-UHFFFAOYSA-N N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamide Chemical compound CN1C=NC(C=2SC3=C(OC=4C(=CC(NC(=S)NC(=O)CC=5C=CC=CC=5)=CC=4)F)C=CN=C3C=2)=C1 UFICVEHDQUKCEA-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 238000003559 RNA-seq method Methods 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- HXINDCTZKGGRDE-JPKZNVRTSA-L disodium;[3-[5-[2-[[(3r)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate Chemical compound [Na+].[Na+].CN1C=CC(S(=O)(=O)N2C[C@@H](CCC2)NC=2N=C(C=CN=2)C=2N3C=COC3=NC=2C=2C=C(OCOP([O-])([O-])=O)C=CC=2)=N1 HXINDCTZKGGRDE-JPKZNVRTSA-L 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950007540 glesatinib Drugs 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- MMNNTJYFHUDSKL-UHFFFAOYSA-N methyl n-[6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-1h-benzimidazol-2-yl]carbamate Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(C1=CC=CC=C1C1=O)(O)N1C1=CC(Cl)=CC=C1C MMNNTJYFHUDSKL-UHFFFAOYSA-N 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229950000846 onartuzumab Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229960004836 regorafenib Drugs 0.000 claims 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 229950003238 rilotumumab Drugs 0.000 claims 1
- 235000002020 sage Nutrition 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 229950005976 tivantinib Drugs 0.000 claims 1
- 230000036210 malignancy Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
1. Способ лечения пациента со злокачественной опухолью, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.2. Способ лечения пациента со злокачественной опухолью, которая характеризуется повышенной вероятностью развития устойчивости к антагонисту B-raf, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.3. Способ увеличения и/или восстановления чувствительности к антагонисту B-raf, предусматривающий введение пациенту со злокачественной опухолью эффективного количества антагониста B-raf и антагониста c-met.4. Способ увеличения периода чувствительности к антагонисту B-raf, предусматривающий введение пациенту со злокачественной опухолью эффективного количества антагониста B-raf и антагониста c-met.5. Способ лечения пациента с устойчивой к антагонисту B-raf злокачественной опухолью, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.6. Способ увеличения длительности ответа на антагонист B-raf, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.7. Способ замедления или предотвращения развития у пациента злокачественной опухоли с опосредованной HGF устойчивостью к антагонисту B-raf, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.8. Способ по п. 7, при котором злокачественная опухоль пациента, как было показано, экспрессирует биомаркер B-raf.9. Способ по п. 8, при котором биомаркер B-raf представляет собой B-raf V600.10. Способ по п. 8, причем биомаркер B-raf представляет собой B-raf V600E.11. Способ по любому из пп. 8-10, при котором экспрессию биомаркера мутантного B-raf в злокачеств
Claims (43)
1. Способ лечения пациента со злокачественной опухолью, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.
2. Способ лечения пациента со злокачественной опухолью, которая характеризуется повышенной вероятностью развития устойчивости к антагонисту B-raf, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.
3. Способ увеличения и/или восстановления чувствительности к антагонисту B-raf, предусматривающий введение пациенту со злокачественной опухолью эффективного количества антагониста B-raf и антагониста c-met.
4. Способ увеличения периода чувствительности к антагонисту B-raf, предусматривающий введение пациенту со злокачественной опухолью эффективного количества антагониста B-raf и антагониста c-met.
5. Способ лечения пациента с устойчивой к антагонисту B-raf злокачественной опухолью, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.
6. Способ увеличения длительности ответа на антагонист B-raf, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.
7. Способ замедления или предотвращения развития у пациента злокачественной опухоли с опосредованной HGF устойчивостью к антагонисту B-raf, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.
8. Способ по п. 7, при котором злокачественная опухоль пациента, как было показано, экспрессирует биомаркер B-raf.
9. Способ по п. 8, при котором биомаркер B-raf представляет собой B-raf V600.
10. Способ по п. 8, причем биомаркер B-raf представляет собой B-raf V600E.
11. Способ по любому из пп. 8-10, при котором экспрессию биомаркера мутантного B-raf в злокачественной опухоли пациента определяют с использованием способа, предусматривающего (a) проведение одного или нескольких из определения профиля генной экспрессии, анализа гибридизации на основе ПЦР, гибридизации in situ, 5′-нуклеазного анализа, анализа обнаружения мутации, секвенирования РНК, микрочипового анализа, SAGE, техники MassARRAY или FISH на образце и (b) определение экспрессии биомаркера мутантного B-raf в образце.
12. Способ по п. 11, при котором экспрессию биомаркера мутантного B-raf в злокачественной опухоли пациента определяют с использованием способа, предусматривающего (a) проведение ПЦР на геномной ДНК, экстрагированной из образца злокачественной опухоли пациента и (b) определение экспрессии биомаркера мутантного B-raf в образце.
13. Способ по любому из пп. 7-10, 12, при котором злокачественная опухоль пациента, как было показано, экспрессирует биомаркер c-met.
14. Способ по п. 13, при котором биомаркер c-met представляет собой полипептид.
15. Способ по п. 14, при котором экспрессию биомаркера c-met определяют с использованием иммуногистохимии (ИГХ).
16. Способ по п. 15, при котором экспрессию биомаркера c-met определяют путем определения экспрессии фактора роста гепатоцитов (HGF).
17. Способ по п. 16, при котором HGF экспрессируется в опухоли или строме опухоли.
18. Способ по п. 16, при котором экспрессию HGF определяют в сыворотке пациента.
19. Способ по любому из пп. 7-10, 12, 14-18, при котором антагонист c-met представляет собой антагонистическое антитело к c-met.
20. Способ по любому из пп. 7-10, 12, 14-18, причем антагонист c-met представляет собой один или несколько из онартузумаба, кризотиниба, тивантиниба, кабозантиниба, MGCD-265, фиклатузумаба, гуманизированного TAK-701, рилотумумаба, форетиниба, h224G11, DN-30, MK-2461, E7050, MK-8033, PF-4217903, AMG208, JNJ-38877605, EMD1204831, INC-280, LY-2801653, SGX-126, RP1040, LY2801653, BAY-853474 и/или LA480.
21. Способ по любому из пп. 7-10, 12, 14-18, при котором антагонист B-raf представляет собой один или несколько из сорафениба, PLX4720, PLX-3603, GSK2118436, GDC-0879, N-(3-(5-(4-хлорфенил)-1H-пирроло[2,3-b]пиридин-3-карбонил)-2,4-дифторфенил)пропан-1-сульфонамида, вемурафениба, GSK 2118436, RAF265 (Novartis), XL281, ARQ736, BAY73-4506.
22. Способ по п. 21, при котором антагонист B-raf представляет собой вемурафениб.
23. Способ по п. 21, при котором антагонист B-raf представляет собой GSK 2118436.
24. Способ по любому из пп. 7-10, 12, 14-18, 22-23, при котором антагонист B-raf и антагонист c-met вводят одновременно.
25. Способ по любому из пп. 7-10, 12, 14-18, 22-23, при котором антагонист B-raf и антагонист c-met вводят последовательно.
26. Способ по п. 25, при котором антагонист B-raf вводят перед введением антагониста c-met.
27. Способ по п. 26, при котором антагонист c-met вводят перед введением антагониста B-raf.
28. Способ по любому из пп. 7-10, 12, 14-18, 22-23, 26-27, дополнительно предусматривающий введение указанному субъекту по меньшей мере одного дополнительного вида лечения.
29. Способ по любому из пп. 7-10, 12, 14-18, 22-23, 26-27, при котором злокачественная опухоль представляет собой меланому, рак толстой и прямой кишки, рак яичника, рак молочной железы или папиллярный рак щитовидной железы.
30. Способ по п. 29, при котором злокачественная опухоль представляет собой меланому, которая, как было показано, экспрессирует B-raf V600.
31. Способ по любому из пп. 7-10, 12, 14-18, 22-23, 26-27, 30, при котором злокачественная опухоль является устойчивой к антагонисту B-raf.
32. Способ по любому из пп. 7-10, 12, 14-18, 22-23, 26-27, 30, при котором пациент ранее не получал лечение с помощью антагониста B-raf.
33. Способ определения экспрессии биомаркера c-met, предусматривающий стадию определения того, экспрессирует ли злокачественная опухоль пациента биомаркер c-met, причем экспрессия биомаркера c-met указывает на то, что пациент представляет собой кандидата для лечения с помощью антагониста c-met и антагониста B-raf: для увеличения чувствительности злокачественной опухоли пациента к антагонисту B-raf, восстановления чувствительности злокачественной опухоли пациента к антагонисту B-raf, для увеличения периода чувствительности злокачественной опухоли пациента к антагонисту B-raf и/или профилактики развития опосредованной HGF устойчивости к антагонисту B-raf у злокачественной опухоли пациента.
34. Способ идентификации пациента в качестве кандидата для лечения с помощью антагониста B-raf и антагониста c-met, предусматривающий (a) определение того, что злокачественная опухоль пациента экспрессирует c-met биомаркер; и (b) идентификацию пациента в качестве кандидата для лечения с помощью антагониста B-raf и антагониста с-met.
35. Способ идентификации пациента в качестве подверженного риску развития устойчивости к антагонисту B-raf, предусматривающий (a) определение того, что злокачественная опухоль пациента экспрессирует c-met биомаркер; и (b) идентификацию пациента в качестве подверженного риску развития устойчивости к антагонисту B-raf.
36. Способ по п. 34 или 35, при котором после стадий (a) и (b) пациент получает лечение с помощью эффективного количества антагониста c-met и антагониста B-raf.
37. Способ определения терапевтической эффективности антагониста B-raf для лечения злокачественной опухоли у пациента, предусматривающий определение присутствия биомаркера c-met и/или биомаркера B-raf в образце, полученном от указанного пациента, с помощью иммуноанализа, ELISA, анализа гибридизации, ПЦР, 5′-нуклеазного анализа, ИГХ и/или RT-ПЦР, и выбор пациента для лечения с помощью антагониста B-raf.
38. Способ по п. 37, дополнительно предусматривающий выбор пациента для лечения с помощью антагониста c-met.
39. Способ по п. 38, дополнительно предусматривающий лечение пациента с помощью эффективного количества антагониста B-raf и антагониста c-met.
40. Способ определения прогноза для пациента с меланомой, предусматривающий определение экспрессии биомаркера c-met в образце от пациента, причем биомаркер c-met представляет собой HGF, и экспрессия HGF представляет собой прогностический признак для злокачественной опухоли у субъекта.
41. Набор, содержащий антагонист c-met и антагонист B-raf.
42. Набор по п. 41, дополнительно содержащий инструкции относительно способа лечения пациента с меланомой, предусматривающие введение эффективного количества антагониста c-met и антагониста B-raf пациенту.
43. Изделие, содержащее антагонист c-met в фармацевтически приемлемом носителе, упакованный вместе с листком-вкладышем, на котором указано, что антагонист c-met предназначен для лечения пациента с меланомой на основании экспрессии биомаркера B-raf, причем лечение проводят в комбинации с антагонистом B-raf.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161536436P | 2011-09-19 | 2011-09-19 | |
US61/536,436 | 2011-09-19 | ||
US201161551328P | 2011-10-25 | 2011-10-25 | |
US61/551,328 | 2011-10-25 | ||
US201261598783P | 2012-02-14 | 2012-02-14 | |
US61/598,783 | 2012-02-14 | ||
US201261641139P | 2012-05-01 | 2012-05-01 | |
US61/641,139 | 2012-05-01 | ||
PCT/US2012/056106 WO2013043715A1 (en) | 2011-09-19 | 2012-09-19 | Combination treatments comprising c-met antagonists and b-raf antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014114617A true RU2014114617A (ru) | 2015-10-27 |
Family
ID=46970439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014114617/10A RU2014114617A (ru) | 2011-09-19 | 2012-09-19 | Комбинированные виды лечения, содержащие антагонисты с-мет и антагонисты b-raf |
Country Status (15)
Country | Link |
---|---|
US (2) | US20130078252A1 (ru) |
EP (1) | EP2758055A1 (ru) |
JP (1) | JP2014534949A (ru) |
KR (1) | KR20140064971A (ru) |
CN (1) | CN103930111A (ru) |
AR (1) | AR087918A1 (ru) |
AU (1) | AU2012312515A1 (ru) |
BR (1) | BR112014006419A2 (ru) |
CA (1) | CA2846630A1 (ru) |
IL (1) | IL231056A0 (ru) |
MX (1) | MX2014002990A (ru) |
RU (1) | RU2014114617A (ru) |
SG (1) | SG11201400724SA (ru) |
WO (1) | WO2013043715A1 (ru) |
ZA (1) | ZA201401370B (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2585488C2 (ru) | 2009-11-05 | 2016-05-27 | Дженентек, Инк. | Способы и композиция для секреции гетерологичных полипептидов |
CN104487087A (zh) * | 2012-07-27 | 2015-04-01 | 基因泰克公司 | 治疗fgfr3相关疾患的方法 |
WO2014138338A1 (en) * | 2013-03-06 | 2014-09-12 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
CA2901384A1 (en) * | 2013-03-15 | 2014-09-18 | Intermune, Inc. | Proteomic ipf markers |
SG10201906270VA (en) | 2013-03-21 | 2019-08-27 | Novartis Ag | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
KR101538385B1 (ko) * | 2013-09-02 | 2015-07-29 | 가톨릭대학교 산학협력단 | 크리조티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물 |
SG11201605207PA (en) * | 2013-12-26 | 2016-07-28 | Ignyta Inc | Pyrazolo[1,5-a]pyridine derivatives and methods of their use |
MA39746A (fr) | 2014-03-14 | 2021-04-28 | Hoffmann La Roche | Compositions de sécrétion de polypeptides hétérologues et procédés associés |
BR112016021383A2 (pt) * | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
US20150283237A1 (en) * | 2014-04-02 | 2015-10-08 | Mitchell S. Felder | Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer |
US10028958B2 (en) | 2014-04-19 | 2018-07-24 | Massachusetts Institute Of Technology | Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors |
TW201613919A (en) | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US20170306415A1 (en) * | 2014-10-01 | 2017-10-26 | Merrimack Phamaceuticals, Inc. | Predicting tumor responses to antibodies against hepatocyte growth factor (hgf) and/or its cognate receptor, c-met |
JP2019525934A (ja) * | 2016-07-29 | 2019-09-12 | イーライ リリー アンド カンパニー | 癌の治療に使用するためのメレスチニブおよび抗pd−l1または抗pd−1阻害剤を用いた組み合わせ治療 |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
MX2019008458A (es) | 2017-01-17 | 2019-12-02 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos. |
UY38349A (es) * | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
CN113234090B (zh) * | 2021-04-23 | 2022-07-29 | 中国药科大学 | 靶向泛素化降解FoxM1的化合物或其可药用的盐、制备方法及用途 |
Family Cites Families (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5310893A (en) | 1986-03-31 | 1994-05-10 | Hoffmann-La Roche Inc. | Method for HLA DP typing |
CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
US5604099A (en) | 1986-03-13 | 1997-02-18 | Hoffmann-La Roche Inc. | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4851331A (en) | 1986-05-16 | 1989-07-25 | Allied Corporation | Method and kit for polynucleotide assay including primer-dependant DNA polymerase |
US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
US5693517A (en) | 1987-06-17 | 1997-12-02 | Roche Molecular Systems, Inc. | Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions |
US5561058A (en) | 1986-08-22 | 1996-10-01 | Hoffmann-La Roche Inc. | Methods for coupled high temperatures reverse transcription and polymerase chain reactions |
US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
CA1340843C (en) | 1987-07-31 | 1999-12-07 | J. Lawrence Burg | Selective amplification of target polynucleotide sequences |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US5639611A (en) | 1988-12-12 | 1997-06-17 | City Of Hope | Allele specific polymerase chain reaction |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5137806A (en) | 1989-12-11 | 1992-08-11 | Board Of Regents, The University Of Texas System | Methods and compositions for the detection of sequences in selected DNA molecules |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69131891T2 (de) | 1990-02-16 | 2000-06-15 | Hoffmann La Roche | Verbesserungen in der spezifität und zweckmässigkeit der polymerase-kettenreaktion |
CA2084987C (en) | 1990-06-11 | 2007-02-13 | Larry Gold | Nucleic acid ligands |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69128520T2 (de) | 1990-10-31 | 1998-07-09 | Tosoh Corp | Verfahren zum Nachweis oder Quantifizierung von Zielnukleinsäuren |
JPH04234422A (ja) | 1990-10-31 | 1992-08-24 | Internatl Business Mach Corp <Ibm> | 二重硬化エポキシバックシール処方物 |
ZA918965B (en) | 1990-11-13 | 1992-08-26 | Siska Diagnostics Inc | Nucleic acid amplification by two-enzyme,self-sustained sequence replication |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
US5994056A (en) | 1991-05-02 | 1999-11-30 | Roche Molecular Systems, Inc. | Homogeneous methods for nucleic acid amplification and detection |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP0540997A1 (en) | 1991-11-05 | 1993-05-12 | F. Hoffmann-La Roche Ag | Methods and reagents for HLA class I DNA typing |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
ATE198358T1 (de) | 1992-04-27 | 2001-01-15 | Dartmouth College | Detektion von gensequenzen in biologischen flüssigkeiten |
US5338671A (en) | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5491063A (en) | 1994-09-01 | 1996-02-13 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5571673A (en) | 1994-11-23 | 1996-11-05 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5773258A (en) | 1995-08-25 | 1998-06-30 | Roche Molecular Systems, Inc. | Nucleic acid amplification using a reversibly inactivated thermostable enzyme |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
ATE428719T1 (de) | 1999-07-29 | 2009-05-15 | Gilead Sciences Inc | Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors |
EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING A POLYPEPTIDE |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
SI1773885T1 (sl) | 2004-08-05 | 2010-08-31 | Genentech Inc | Humanizirani anti-CMET antagonisti |
EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US20060211073A1 (en) * | 2005-03-21 | 2006-09-21 | May Earl W | Assay for B-Raf activity based on intrinsic MEK ATPase activity |
CN102603581B (zh) | 2005-06-22 | 2015-06-24 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
AU2007224020A1 (en) | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
CA2646048A1 (en) | 2006-03-30 | 2007-11-08 | Novartis Ag | Compositions and methods of use for antibodies of c-met |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
JP4686634B2 (ja) | 2006-06-02 | 2011-05-25 | アベオ ファーマシューティカルズ, インコーポレイテッド | 肝細胞成長因子(hgf)結合蛋白質 |
EP2043675A2 (en) * | 2006-07-07 | 2009-04-08 | Washington State University Research Foundation | C-met receptor regulation by angiotensin iv (at4) receptor ligands |
KR100829972B1 (ko) | 2006-07-14 | 2008-05-16 | 재단법인서울대학교산학협력재단 | 항-hgf/sf 인간화 항체 및 이의 제조방법 |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
WO2009111280A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
US20110003809A1 (en) | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
EP2265608A2 (en) | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
TW200940539A (en) | 2008-02-29 | 2009-10-01 | Array Biopharma Inc | RAF inhibitor compounds and methods of use thereof |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US8637554B2 (en) * | 2008-05-07 | 2014-01-28 | The Trustees Of The University Of Pennsylvania | Methods for treating thyroid cancer |
JP5699075B2 (ja) * | 2008-05-14 | 2015-04-08 | アムジエン・インコーポレーテツド | 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ |
WO2010045344A1 (en) * | 2008-10-17 | 2010-04-22 | Genentech, Inc. | Combination therapy comprising a c-met antagonist and a vegf antagonist |
PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
AU2010213696B2 (en) * | 2009-02-12 | 2015-10-01 | Arqule, Inc. | A composition comprising (-) -trans-3- (5, 6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine- 2, 5-dione in combination with a second anti-proliferative agent |
EP2287197A1 (en) | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
CN102859355B (zh) * | 2009-08-24 | 2015-10-07 | 基因泰克公司 | 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性 |
KR101671378B1 (ko) | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
US9238832B2 (en) | 2009-12-11 | 2016-01-19 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids |
SG10201408229WA (en) | 2010-08-31 | 2015-02-27 | Genentech Inc | Biomarkers and methods of treatment |
-
2012
- 2012-09-19 MX MX2014002990A patent/MX2014002990A/es unknown
- 2012-09-19 BR BR112014006419A patent/BR112014006419A2/pt not_active IP Right Cessation
- 2012-09-19 CA CA 2846630 patent/CA2846630A1/en not_active Abandoned
- 2012-09-19 JP JP2014530956A patent/JP2014534949A/ja active Pending
- 2012-09-19 SG SG11201400724SA patent/SG11201400724SA/en unknown
- 2012-09-19 US US13/622,878 patent/US20130078252A1/en not_active Abandoned
- 2012-09-19 AR ARP120103446 patent/AR087918A1/es unknown
- 2012-09-19 CN CN201280055708.6A patent/CN103930111A/zh active Pending
- 2012-09-19 EP EP12768982.6A patent/EP2758055A1/en not_active Withdrawn
- 2012-09-19 WO PCT/US2012/056106 patent/WO2013043715A1/en active Application Filing
- 2012-09-19 RU RU2014114617/10A patent/RU2014114617A/ru not_active Application Discontinuation
- 2012-09-19 AU AU2012312515A patent/AU2012312515A1/en not_active Abandoned
- 2012-09-19 KR KR20147010162A patent/KR20140064971A/ko not_active Application Discontinuation
-
2014
- 2014-02-20 IL IL231056A patent/IL231056A0/en unknown
- 2014-02-21 ZA ZA2014/01370A patent/ZA201401370B/en unknown
- 2014-11-06 US US14/535,071 patent/US20150125452A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG11201400724SA (en) | 2014-04-28 |
AU2012312515A1 (en) | 2014-03-13 |
US20150125452A1 (en) | 2015-05-07 |
US20130078252A1 (en) | 2013-03-28 |
JP2014534949A (ja) | 2014-12-25 |
ZA201401370B (en) | 2015-09-30 |
KR20140064971A (ko) | 2014-05-28 |
MX2014002990A (es) | 2014-05-21 |
CN103930111A (zh) | 2014-07-16 |
EP2758055A1 (en) | 2014-07-30 |
CA2846630A1 (en) | 2013-03-28 |
AR087918A1 (es) | 2014-04-23 |
WO2013043715A1 (en) | 2013-03-28 |
BR112014006419A2 (pt) | 2018-08-07 |
IL231056A0 (en) | 2014-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014114617A (ru) | Комбинированные виды лечения, содержащие антагонисты с-мет и антагонисты b-raf | |
De Robertis et al. | Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer | |
Lipsyc et al. | Impact of somatic mutations on patterns of metastasis in colorectal cancer | |
CN109790582B (zh) | 基于c-maf状态的乳腺癌治疗性治疗 | |
Scagliotti et al. | ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development | |
Patel et al. | A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study) | |
Ulivi et al. | Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study | |
Bando et al. | Therapeutic landscape and future direction of metastatic colorectal cancer | |
JP2017516458A5 (ru) | ||
US11208690B2 (en) | Prognostic assay for squamous cell lung carcinoma | |
RU2013114360A (ru) | Биомаркеры и способы лечения | |
Jin et al. | Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases | |
CN111565725A (zh) | 基于c-maf状态的乳腺癌的治疗性处理 | |
Rau et al. | Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers | |
Lee et al. | Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer | |
Osman et al. | Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients | |
Yong et al. | Metastatic profile of colorectal cancer: interplay between primary tumor location and KRAS status | |
Osumi et al. | Cetuximab treatment for metastatic colorectal cancer with KRAS p. G13D mutations improves progression-free survival | |
Hu et al. | Therapeutic developments in pancreatic cancer | |
Ott et al. | The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status | |
Li et al. | Progranulin expression in breast cancer with different intrinsic subtypes | |
Sun et al. | Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck | |
Reis et al. | HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas | |
Jung et al. | Update on C-cell neuroendocrine neoplasm: prognostic and predictive histopathologic and molecular features of medullary thyroid carcinoma | |
Mushtaq et al. | Comparison of different molecular subtypes with 14% Ki-67 Cut-off threshold in breast cancer patients of Pakistan-An indication of poor prognosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150921 |